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Thrombotic thrombocytopenic purpura (TTP) is a multisystem disorder characterized by
microvascular aggregation of platelets and fibrin strands causing thrombocytopenia, microan-
giopathic hemolytic anemia, and organ dysfunction. TTP can develop as a result of a deficiency
in ADAMTS13 enzyme activity due to either a genetic defect or, more commonly, the develop-
ment of anti-ADAMTS13 autoantibodies. TTP can also be associated with pregnancy, organ
transplant, lupus, infections, and drugs. Here, we present a case of TTP that developed shortly
after the start of clopidogrel treatment for acute ischemic stroke and acute myocardial infarc-
tion, and describe the clinical presentation, refractory course of the disease, and successful
induction of remission through the use of rituximab in a setting of pre-existing autoimmune dis-
eases.
 2015 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Thrombotic thrombocytopenic purpura (TTP) and hemolytic
uremic syndrome (HUS) are similar disorders classified under
thrombotic microangiopathy (TMA) due to the common
mechanisms of platelet and red blood cells (RBC)
destruction in the microvasculature, and similar histologic
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organs. Both TTP and HUS are characterized by the deposi-
tion of loose platelets and fibrin strands in small vessels,
causing mechanical shearing of RBCs and agglutination of
platelets and resulting in microangiopathic hemolytic ane-
mia (MAHA) and thrombocytopenia. Although it is rare,
TTP can cause chronic remitting and relapsing illness due
to congenital deficiency of von Willebrand factor (vWF)-
cleaving protease called ADAMTS13. However, most cases
of TTP are acquired (also known as idiopathic TTP) and
caused by IgG autoantibodies that inhibit ADAMTS13 enzy-
matic activity. Normally, ADAMTS13 regulates vWF activity
by cleaving high-molecular weight vWF multimers, and pre-
vents platelet accumulation and thrombosis in capillaries
and arterioles. Failure to cleave the vWF multimers in TTP
by ADAMTS13 leads to accumulation of large vWF multimers
facilitating platelet accumulation and microvascular throm-
bosis, which results in tissue ischemia of the affected organs
and leads to variable degrees of neurologic symptoms and
renal impairment. The classic pentad of MAHA, thrombocy-
topenia, neurologic symptoms, renal failure, and fever is
present in only 5% of patients, and evidence of TMA (MAHA
and thrombocytopenia) without another apparent etiology
is enough to make a working diagnosis of TTP/HUS.
Typical laboratory findings for TTP include decreased
platelet count, elevated lactate dehydrogenase (LDH), neg-
ative direct anti-globulin test (DAT), and fragmentation
hemolysis (schistocytes) on the blood smear. Levels of cre-
atinine and blood urea nitrogen depend on the presence and
severity of renal involvement. Schistocytes are characteris-
tic for TTP, but can also be present with other causes of
fragmentation hemolysis, e.g., disseminated intravascular
coagulation (DIC), prosthetic valve hemolysis, malignant
hypertension, preeclampsia/HELLP syndrome, and vasculitis
[systemic lupus erythematosus (SLE), scleroderma]. In con-
trast to DIC, typically in TTP, prothrombin time, activated
partial thromboplastin time, fibrinogen, and D-dimer levels
are normal. A severely depressed (<10%) level of ADAMTS13
activity is present in TTP, while ADAMTS13 activity is normal
in HUS. This distinction is important clinically, but not
required to make a working diagnosis of TTP, and to initiate
lifesaving treatment with plasma exchange (PLEX).
Case report
A 43-year-old woman with past medical history of hyperten-
sion, hyperlipidemia, Sjogren’s syndrome (SS), rheumatoid
arthritis (RA), and obesity was admitted from the emer-
gency room for rapid onset right-sided paresthesia from
acute left-thalamic ischemic stroke. She developed angina
while in the hospital, and was diagnosed with non-ST seg-
ment elevation myocardial infarction (NSTEMI). Coronary
angiogram showed nonobstructive coronary artery disease,
and laboratory studies revealed normal blood counts, biliru-
bin, and creatinine. The stroke and myocardial infarction
were presumed secondary to accelerated hypertension.
She was started on aspirin, atorvastatin, clopidogrel, carve-
dilol, and losartan, and was discharged home after 5 days of
hospitalization. The patient presented again 2-weeks later
with an approximately 3-day history of worsening fatigue,
jaundice, and generalized rash. Physical exam was notablefor generalized petechial rash, scleral icterus, dark urine,
normal mental status, and stable vital signs. Abnormal lab-
oratory studies included a platelet count of 8000/mm3, LDH
of 797 IU/L, hemoglobin of 10.5 gm/dL, creatinine of
2.3 mg/dL (against a baseline of 1.1 two-weeks prior),
bilirubin of 4 mg/dL, and haptoglobin <20 mg/dL (normal
range: 37–246 mg/dL). Peripheral blood smear showed
three schistocytes per high power field, polychromasia,
and severe thrombocytopenia. A DAT (Coomb’s test) was
negative. The patient was diagnosed with TTP/HUS, clopi-
dogrel was discontinued, and she was started promptly on
PLEX and 1 mg/kg prednisone. She initially responded to
therapy with an improvement in both platelet counts and
LDH levels, but then became refractory to PLEX on day 7,
as shown in Figure 1. She also deteriorated clinically on
day 7, with new onset anginal chest pain, which was con-
cerning for coronary ischemia, that improved with a nitro-
glycerine infusion. She also complained of new right-sided
paresthesia, and magnetic resonance imaging of the brain
confirmed a new acute left lentiform and caudate nuclei
infarcts. As a result, we started her on 375 mg/m2 rituximab
IV, escalated glucocorticoid therapy to 1 gram methylpred-
nisolone IV daily, and continued daily PLEX. The concomi-
tant use of PLEX, rituximab, and steroid was complicated
by transfusion-associated circulatory overload, which
responded to IV diuretics, gradual weaning off of the PLEX
and steroids, and supportive care. Over the next several
days, she continued to improve clinically and went into
complete remission from TTP after receiving a total of 24
PLEX treatments, three weekly dosages of rituximab, and
a tapering course of prednisone over 3 weeks.
Discussion
Our patient had a positive ADAMTS13 antibody of >8
(normal: <0.5 inhibitor units), with a decrease in ADAMTS13
activity to <5 (normal: 68–163%). This was consistent with
TTP, which is the disorder usually described in adults, unlike
HUS, which is more common in children and associated with
normal ADAMTS13 activity and absence of the inhibitor anti-
body. Many studies do not distinguish between TTP and HUS,
and combine them under the comprehensive term TTP/HUS
syndrome, since their presenting features and initial man-
agement in adults are essentially the same. Although the
levels of ADAMTS13 activity and inhibitor antibody help dif-
ferentiate between TTP and HUS, one should not wait for
the results of these tests to start therapy. When neurologi-
cal manifestations are more dominant, with renal abnormal-
ities being minimal or absent, the condition is more likely to
be TTP; whereas, when acute renal failure is the dominant
clinical manifestation, the condition is more likely to be
HUS. HUS often presents in children, following bloody diar-
rhea due to a shiga-toxin producing strain of Escherichia coli
(O157:H7), and resolves spontaneously with supportive care
(D+ HUS). Some HUS patients can present without diarrheal
prodrome, and are classified to have D HUS or atypical
HUS. HUS occurs due to dysregulation of complement regu-
latory proteins. In TTP, in addition to renal and neurologic
abnormalities, patients may rarely present with cardiac
involvement secondary to platelet thrombi, leading to
arrhythmias, myocardial infarctions, heart failure, or even
Figure 1 Lactate dehydrogenase and platelet count versus time with medical management.
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genetic defect of ADAMTS13, leading to reduced ADAMTS13
activity [2]. However, there have been cases reported of
patients with severely reduced ADAMTS13 activity who have
no hematologic abnormalities, as well as cases of patients
who have persistent reduced ADAMTS13 activity, even after
recovery from TTP [3,4]. Additionally, mouse-model studies
of homozygous ADAMTS13 deficiency demonstrated the
need for inflammatory or prothrombotic stimuli to initiate
a clinical syndrome resembling TTP [5,6].
However, the reduced ADAMTS13 activity in acquired
TTP is the result of an autoimmune process, wherein inhibi-
tory autoantibodies are produced against ADAMTS13.
Severely reduced ADAMTS13 activity was also associated
with other autoimmune disorders, such as SLE, suggesting
a linkage to broader autoimmune disorders and/or relation-
ships to HLA regions [7]. TTP was also described as being
associated with other conditions, including pregnancy,
organ transplant, infections, and disseminated malignancy.
TTP-like syndromes can be caused by certain drugs, such as
ticlopidine (frequency: 1 in 2000 to 5000), clopidogrel (fre-
quency: <1 in 20,000), quinine, trimethoprim, interferon,
simvastatin, tacrolimus, mitomycin C, and gemcitabine
[8]. The pathogenesis of drug-induced TTP is diverse, but
some are associated with autoantibodies to ADAMTS13,
while many others are due to other mechanisms, such as
direct endothelial injury. In the case of our patient, we
believed that TTP was induced by clopidogrel, as the
patient developed TTP 2 weeks after initiation of this drug.
The mechanism of clopidogrel-induced TTP is not fully
understood, as many of these patients have decreased
ADAMTS13 activity, and a minority of patients has normal
ADAMTS13 activity. A contributory role for the concomitant
use of statins has been suggested, but not confirmed [9].
The antiplatelet drug ticlopidine has fallen out of favor
due to higher association with TTP. TTP caused by
clopidogrel is very rare, typically occurring 2-weekspostadministration, and responds well to PLEX in the major-
ity of cases, but can relapse in some cases [10]. The fact
that our patient had severely decreased ADAMTS13 activity
and high titer ADAMTS13 autoantibodies may suggest the
possibility of contributions from pre-existing autoimmune
processes (SS and/or RA) to trigger ADAMTS13-antibody pro-
duction, with clopidogrel acting as a hapten. This raises the
question of whether the initial presentation of stroke and
NSTEMI by our patient shortly before development of TTP
was also related to the underlying autoimmunity, and that
TTP was provoked or accelerated by clopidogrel use. It is
unknown how clopidogrel induces production of ADAMTS13
autoantibodies in some cases, and can cause TTP indepen-
dent of ADAMTS13 in others.
The standard treatment for TTP relies upon therapeutic
PLEX, which replaces ADAMTS13 and removes circulating
inhibitory autoantibodies. Mortality from TTP was previ-
ously very high (>90%) before the advent of PLEX, but has
decreased to <20% with PLEX treatment. Our patient ini-
tially responded with a decline in LDH levels and a rise in
platelet count during the 1st week of steroid and daily PLEX
treatments (Figure 1). However, the patient became refrac-
tory to PLEX on day 7. While PLEX treatment is successful in
many patients, 10–20% will have a transient or incomplete
response to therapy, and this group of TTP patients are at
high risk of death [11]. Case reports and small studies have
documented success with the use of rituximab in the treat-
ment of such refractory cases, with substantial improve-
ment in the outcomes [12,13]. Rituximab, a humanized
monoclonal antibody against CD20 antigen on the surface
of B-lymphocytes, can cause depletion of CD20-expressing
B lymphocytes, which would otherwise differentiate into
plasma cells that secrete the inhibitory antibodies. The
mechanisms proposed for lymphocyte depletion include
complement-dependent cytotoxicity, direct apoptosis, and
antibody-dependent cellular cytotoxicity. Rituximab is
generally well tolerated, aside from the risk of infusion
Table 1 ADAMTS13 activity and ADAMTS13 inhibitor with
duration of therapy.









Note: Normal ADAMTS13 activity is >67% (range: 68–163%), and
the normal titer for ADAMTS13 inhibitor antibody is <0.5 inhibitor
units. ADAMTS13 activity was ordered with reflex testing for the
inhibitor in case of low ADAMTS13 activity. NA = not applicable.
Clopidogrel-induced TTP treated with rituximab 79reactions and increased risk of infections. The majority of
patients who are refractory to PLEX respond to a single dose
of rituximab and improvement is seen within 2 weeks, but
the exact dosage and duration of rituximab therapy required
is unknown, and long-term follow up data are still evolving.
Our patient continued to show increasing ADAMTS13 activity
and decreasing ADAMTS13 inhibitor during the first 3 weeks
(Table 1), and required three weekly doses of rituximab to
induce complete remission. Also unknown is whether there
is any role for maintenance therapy using rituximab to pre-
vent TTP relapse. Others have advocated preemptive ritux-
imab infusions after remission in order to prevent relapses
in patients with persistent severe ADAMTS13 deficiency
(<10%), because such patients are known for higher relapses
[13]. We administered five additional weekly dosages of
rituximab for consolidation and did not offer any mainte-
nance rituximab therapy. The patient remains in complete
remission with complete renal and neurologic recovery after
13 months of follow up.
In conclusion, despite prompt recognition and immediate
PLEX treatment, some TTP patients fail to respond, or
respond only transiently. Such patients are at high risk of
early death, and rituximab therapy in this situation can be
lifesaving. Clopidogrel-induced TTP is very rare and usually
responds to PLEX treatment. However, in refractory cases,
response to rituximab has been observed with sustained
remission. Clopidogrel-induced TTP should be considered
in an acutely ill patient with thrombocytopenia, especially
in the first few weeks after drug treatment is initiated.
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